Non-Hodgkin’s lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint

References

• Guevara-Canales JO, Morales-Vadillo R, de Faria PE, et al. Systematic review of lymphoma in oral cavity and maxillofacial region. Acta Odontol Latinoam. 2011;24:245–250.
   PubMedGoogle Scholar
• Corti M, Villafane M, Bistmans A, et al. Primary extranodal non-hodgkin lymphoma of the head and neck in patients with acquired immunodeficiency syndrome: a clinicopathologic study of 24 patients in a single hospital of infectious diseases in Argentina. Int Arch Otorhinolaryngol. 2014;18:260–265.
   PubMedGoogle Scholar
• Cox DP, Treseler P, Dong R, et al. Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:814–819.
   PubMed Web of Science ®Google Scholar
• Kojima M, Nakamura N, Shimizu K, et al. Histopathological variation of primary mucosa-associated lymphoid tissue lymphoma of the oral cavity. Pathol Oncol Res. 2007;13:345–349.
   PubMed Web of Science ®Google Scholar
• Rajkumar K, Rao R, Chawla N, et al. Mantle cell lymphoma of the oral cavity with multiple foci: a case report and review of the literature. J Maxillofac Oral Surg. 2015;14:138–144.
   PubMedGoogle Scholar
• Corti M, Minue G, Campitelli A, et al. An aggressive plasmablastic lymphoma of the oral cavity as primary manifestation of acquired immunodeficiency syndrome: case report and literature review. Int Arch Otorhinolaryngol. 2015;19:354–358.
   PubMedGoogle Scholar
• Corti M, Villafane MF, Solari R, et al. Non-Hodgkin lymphomas of the oral cavity in AIDS patients in a reference hospital of infectious diseases in Argentina: report of eleven cases and review of the literature. J Gastrointest Cancer. 2011;42:143–148.
   PubMedGoogle Scholar
• Deyrup AT. Epstein-Barr virus-associated epithelial and mesenchymal neoplasms. Hum Pathol. 2008;39:473–483.
   PubMed Web of Science ®Google Scholar
• Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci. 2001;356:461–473.
   PubMed Web of Science ®Google Scholar
• Shannon-Lowe C, Rickinson AB, Bell AI. Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond B Biol Sci. 2017;372.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Suh CW, Lee SI, et al. Clinical characteristics, pathological distribution, and prognostic factors in non-hodgkin lymphoma of waldeyer’s ring: nationwide Korean study. Korean J Intern Med. 2014;29:352–360.
   PubMed Web of Science ®Google Scholar
• Guevara-Canales JO, Morales-Vadillo R, Cava-Vergiu CE, et al. Survival in patients with oral and maxillofacial diffuse large B-cell lymphoma. Braz Oral Res. 2013;27:349–355.
   PubMed Web of Science ®Google Scholar
• Guevara-Canales JO, Morales-Vadillo R, Sacsaquispe-Contreras SJ, et al. Malignant lymphoma of the oral cavity and the maxillofacial region: overall survival prognostic factors. Med Oral Patol Oral Cir Bucal. 2013;18:e619–26.
   PubMed Web of Science ®Google Scholar
• Sunaba K, Shibuya H, Okada N, et al. Radiotherapy for primary localized (stage I and II) non-Hodgkin’s lymphoma of the oral cavity. Int J Radiat Oncol Biol Phys. 2000;47:179–183.
   PubMed Web of Science ®Google Scholar
• Kolokotronis A, Konstantinou N, Christakis I, et al. Localized B-cell non-Hodgkin’s lymphoma of oral cavity and maxillofacial region: a clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:303–310.
   PubMed Web of Science ®Google Scholar
• Sirsath NT, Lakshmaiah KC, Das U, et al. Primary extranodal non-Hodgkin’s lymphoma of oral cavity–a single centre retrospective study. J Cancer Res Ther. 2014;10:945–950.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Facchetti F, Re A, et al. Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients. Leuk Lymphoma. 2005;46:77–81.
   PubMed Web of Science ®Google Scholar
• Corti M, Solari R, Cangelosi D, et al. Oral cavity lymphoma as secondary AIDS-defining neoplasm in a patient on HAART with immune reconstitution. Rev Soc Bras Med Trop. 2007;40:582–584.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya I, Hk C, Dm C, et al. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification. Head Neck Pathol. 2010;4:181–191.
   PubMedGoogle Scholar
• Sato Y, Onishi N, Morito T, et al. Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype. Cancer Sci. 2009;100:42–46.
   PubMed Web of Science ®Google Scholar
• Rai B, Astekar MS, Manjunatha BS, et al. Diffuse large B cell lymphoma of hard palate: a case report with literature review. J Exp Ther Oncol;11:101–105. 2017
   Google Scholar
• Kini R, Saha A, Naik V. Diffuse large B-cell lymphoma of mandible: a case report. Med Oral Patol Oral Cir Bucal. 2009;14:e421–4.
   PubMed Web of Science ®Google Scholar
• de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology. 2003;43:509–528.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214–1217.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018;131:2307–2319.
   PubMed Web of Science ®Google Scholar
• Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20:5580–5594.
   PubMed Web of Science ®Google Scholar
• Lenz G, Nagel I, Siebert R, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007;204:633–643.
   PubMed Web of Science ®Google Scholar
• Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol. 2011;28:167–177.
   PubMed Web of Science ®Google Scholar
• Shimada K. Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma. Rinsho Ketsueki. 2017;58:2033–2042.
   PubMedGoogle Scholar
• Houldsworth J, Mathew S, Rao PH, et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood. 1996;87:25–29.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Martin P, Roboz GJ. Practical implications of the 2016 revision of the world health organization classification of lymphoid and myeloid neoplasms and acute leukemia. J Clin Oncol. 2017;35:2708–2715.
   PubMed Web of Science ®Google Scholar
• Aa O, Ea B, Surti U, et al. Large B-cell lymphoma of the base of the tongue and oral cavity: a practical approach to identifying prognostically important subtypes. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:338–347.
   PubMed Web of Science ®Google Scholar
• Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol. 2006;17:1434–1440.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18:346–350.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–26.
   PubMed Web of Science ®Google Scholar
• Lee YH, Cho SG, Jung SE, et al. Analysis of treatment outcomes for primary tonsillar lymphoma. Radiat Oncol J. 2016;34:273–279.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zheng Y, Xie J, et al. Long-term tumor-free survival with untreated primary diffuse large B-cell lymphoma of the tonsil: a report of 9 cases. Am J Surg Pathol. 2015;39:1493–1501.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Schwarer AP, McLean C, et al. AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation–treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haematologica. 2007;92:e11–2.
   PubMedGoogle Scholar
• Corti M, de Dios Soler M, Bare P, et al. [AIDS related lymphomas: histopathological subtypes and association with Epstein Barr virus and Human Herpes virus type-8]. Medicina (B Aires). 2010;70:151–158.
   PubMed Web of Science ®Google Scholar
• Corti M, Villafane MF, Bistmans A, et al. Soft-tissue masses as presentation of non-Hodgkin’s lymphoma in AIDS patients. An Bras Dermatol. 2013;88:631–634.
   PubMed Web of Science ®Google Scholar
• Metta H, Corti M, Maranzana A, et al. Unusual case of plasmablastic non-Hodgkin’s lymphoma located in the liver. First Case Reported in an AIDS Patient. Ann Hepatol. 2009;8:242–245.
   PubMed Web of Science ®Google Scholar
• Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18:806–815.
   PubMed Web of Science ®Google Scholar
• Harmon CM, Smith LB. Plasmablastic lymphoma: a review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med. 2016;140:1074–1078.
   PubMed Web of Science ®Google Scholar
• Gaidano G, Cerri M, Capello D, et al. Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol. 2002;119:622–628.
   PubMed Web of Science ®Google Scholar
• Hansra D, Montague N, Stefanovic A, et al. Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. Am J Clin Pathol. 2010;134:710–719.
   PubMed Web of Science ®Google Scholar
• Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34:1686–1694.
   PubMed Web of Science ®Google Scholar
• Maestre L, Tooze R, Canamero M, et al. Expression pattern of XBP1(S) in human B-cell lymphomas. Haematologica. 2009;94:419–422.
   PubMed Web of Science ®Google Scholar
• Kremer M, Ott G, Nathrath M, et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol. 2005;205:92–101.
   PubMed Web of Science ®Google Scholar
• Li F, Ding W, Zuo Z, et al. [Plasmablastic lymphoma: a clinicopathologic analysis of 11 cases with review of literature]. Zhonghua Bing Li Xue Za Zhi. 2016;45:37–42.
   PubMedGoogle Scholar
• Svoboda WE, Aaron GR, Albano EA. North American burkitt’s lymphoma presenting with intraoral symptoms. Pediatr Dent. 1991;13:52–58.
   PubMedGoogle Scholar
• Banthia V, Jen A, Kacker A. Sporadic burkitt’s lymphoma of the head and neck in the pediatric population. Int J Pediatr Otorhinolaryngol. 2003;67:59–65.
   PubMed Web of Science ®Google Scholar
• Jan A, Vora K, Sandor GK. Sporadic burkitt’s lymphoma of the jaws: the essentials of prompt life-saving referral and management. J Can Dent Assoc. 2005;71:165–168.
   PubMedGoogle Scholar
• Kikuchi K, Inoue H, Miyazaki Y, et al. Adult sporadic burkitt lymphoma of the oral cavity: a case report and literature review. J Oral Maxillofac Surg. 2012;70:2936–2943.
   PubMed Web of Science ®Google Scholar
• Magrath IT. African burkitt’s lymphoma. history, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol. 1991;13:222–246.
   PubMedGoogle Scholar
• Wright D. Nailing burkitt lymphoma. Br J Haematol. 2012;156:780–782.
   PubMed Web of Science ®Google Scholar
• Balasubramaniam R, Goradia A, Turner LN, et al. Burkitt lymphoma of the oral cavity: an atypical presentation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:240–245.
   PubMed Web of Science ®Google Scholar
• Ajila V, Gopakumar R, Hegde S, et al. Intraoral burkitt’s lymphoma in an HIV positive patient. Indian J Sex Transm Dis. 2012;33:118–120.
   PubMedGoogle Scholar
• Ardekian L, Rachmiel A, Rosen D, et al. Burkitt’s lymphoma of the oral cavity in Israel. J Craniomaxillofac Surg. 1999;27:294–297.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Nakamine H, Tamaru J, et al. The distinction between burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. Mod Pathol. 2002;15:771–776.
   PubMed Web of Science ®Google Scholar
• Fujita S, Buziba N, Kumatori A, et al. Early stage of Epstein-Barr virus lytic infection leading to the “starry sky” pattern formation in endemic burkitt lymphoma. Arch Pathol Lab Med. 2004;128:549–552.
   PubMed Web of Science ®Google Scholar
• Hui PK, Feller AC, Lennert K. High-grade non-Hodgkin’s lymphoma of B-cell type. I. Histopathology. Histopathology. 1988;12:127–143.
   PubMed Web of Science ®Google Scholar
• Frost M, Newell J, Lones MA, et al. Comparative immunohistochemical analysis of pediatric burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol. 2004;121:384–392.
   PubMed Web of Science ®Google Scholar
• Chuang SS, Ye H, Du MQ, et al. Histopathology and immunohistochemistry in distinguishing burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Pathol. 2007;128:558–564.
   PubMed Web of Science ®Google Scholar
• Jacobson C, LaCasce A. How I treat burkitt lymphoma in adults. Blood. 2014;124:2913–2920.
   PubMed Web of Science ®Google Scholar
• Garcia CF, Weiss LM, Warnke RA. Small noncleaved cell lymphoma: an immunophenotypic study of 18 cases and comparison with large cell lymphoma. Hum Pathol. 1986;17:454–461.
   PubMed Web of Science ®Google Scholar
• Garcia-Ortega FP, Bonnin Otal J, Duran R, et al. [Burkitt lymphoma of a palatine tonsil]. Acta Otorrinolaringol Esp. 1999;50:579–582.
   PubMedGoogle Scholar
• Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–87.
   PubMedGoogle Scholar
• Jaradat JM, Potluri A, Bilodeau EA. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: report of a case in the oral cavity. Indian J Dent Res. 2013;24:384–386.
   PubMedGoogle Scholar
• Chapman CJ, Wright D, Stevenson FK. Insight into burkitt’s lymphoma from immunoglobulin variable region gene analysis. Leuk Lymphoma. 1998;30:257–267.
   PubMed Web of Science ®Google Scholar
• Allday MJ. How does Epstein-Barr virus (EBV) complement the activation of myc in the pathogenesis of burkitt’s lymphoma? Semin Cancer Biol. 2009;19:366–376.
   PubMedGoogle Scholar
• Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116–120.
   PubMed Web of Science ®Google Scholar
• Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436:807–811.
   PubMed Web of Science ®Google Scholar
• Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44:1316–1320.
   PubMed Web of Science ®Google Scholar
• Chapman CJ, Mockridge CI, Rowe M, et al. Analysis of VH genes used by neoplastic B cells in endemic burkitt’s lymphoma shows somatic hypermutation and intraclonal heterogeneity. Blood. 1995;85:2176–2181.
   PubMed Web of Science ®Google Scholar
• Chapman CJ, Zhou JX, Gregory C, et al. VH and VL gene analysis in sporadic burkitt’s lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection. Blood. 1996;88:3562–3568.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Ceribelli M, Pittaluga S, et al. Oncogenic mechanisms in burkitt lymphoma. Cold Spring Harb Perspect Med. 2014;4.
   PubMed Web of Science ®Google Scholar
• Feinberg SM, Ou SH, Gu M, et al. Burkitt’s lymphoma of the base of the tongue: a case report and review of the literature. Ear Nose Throat J. 2007;86:356–360.
   PubMed Web of Science ®Google Scholar
• Beogo R, Nacro B, Ouedraogo D, et al. Endemic burkitt lymphoma of maxillofacial region: results of induction treatment with cyclophosphamide plus methotrexate in West Africa. Pediatr Blood Cancer. 2011;56:1068–1070.
   PubMed Web of Science ®Google Scholar
• Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-associated burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART Era. Adv Hematol. 2012;735392:2012.
   Google Scholar
• Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925–934.
   PubMed Web of Science ®Google Scholar
• Philip T, Lenoir GM, Bryon PA, et al. Burkitt-type lymphoma in France among non-Hodgkin malignant lymphomas in caucasian children. Br J Cancer. 1982;45:670–678.
   PubMed Web of Science ®Google Scholar
• Harabuchi Y, Takahara M, Kishibe K, et al. Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features. Int J Clin Oncol. 2009;14:181–190.
   PubMed Web of Science ®Google Scholar
• Ahn SJ, Jang KA, Choi JH, et al. Nasal and nasal type CD56+ natural killer cell/T-cell lymphoma: a case with rapid progression to bone marrow involvement. Br J Dermatol. 2000;142:1021–1025.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131:2528–2540.
   PubMed Web of Science ®Google Scholar
• Cabrera ME, Eizuru Y, Itoh T, et al. Nasal natural killer/T-cell lymphoma and its association with type “i”/XhoI loss strain Epstein-Barr virus in chile. J Clin Pathol. 2007;60:656–660.
   PubMed Web of Science ®Google Scholar
• Isiksacan V, Topaloglu I, Berkiten G, et al. Two cases of nasal natural killer T-cell lymphoma. Kulak Burun Bogaz Ihtis Derg. 2002;9:376–379.
   PubMedGoogle Scholar
• Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006;106:609–615.
   PubMed Web of Science ®Google Scholar
• Uno M, Tsuchiyama J, Moriwaki A, et al. In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol. 2001;113:1009–1014.
   PubMed Web of Science ®Google Scholar
• Wu X, Li P, Zhao J, et al. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clin Oncol (R Coll Radiol). 2008;20:619–625.
   PubMed Web of Science ®Google Scholar
• Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood. 2001;97:708–713.
   PubMed Web of Science ®Google Scholar
• Harabuchi Y, Yamanaka N, Kataura A, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990;335:128–130.
   PubMed Web of Science ®Google Scholar
• Lei KI, Chan LY, Chan WY, et al. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol. 2000;111:239–246.
   PubMed Web of Science ®Google Scholar
• Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104:243–249.
   PubMed Web of Science ®Google Scholar
• Ishii H, Ogino T, Berger C, et al. Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T-cell lymphoma. J Med Virol. 2007;79:562–572.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017;35:32–39.
   PubMed Web of Science ®Google Scholar
• Takahara M, Nagato T, Kishibe K, et al. Novel treatment for early-stage nasal natural killer/T-cell lymphoma: intra-maxillary arterial infusion chemotherapy with concomitant radiotherapy. Hematol Oncol. 2017;35:158–162.
   PubMed Web of Science ®Google Scholar
• Latchman YE, Liang SC, Wu Y, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A. 2004;101:10691–10696.
   PubMed Web of Science ®Google Scholar
• Nagato T, Ohkuri T, Ohara K, et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother. 2017;66:877–890.
   PubMed Web of Science ®Google Scholar
• Akutsu Y, Murakami K, Kano M, et al. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Esophagus. 2018;15:103–108.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Sasaki M, Morinaga S, et al. Nonsmall cell lung carcinoma with giant cell features expressing programmed death-ligand 1: a report of a patient successfully treated with pembrolizumab. Case Rep Oncol Med. 2018;2018:5863015.
   PubMedGoogle Scholar
• Jo JC, Kim M, Choi Y, et al. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2017;96:25–31.
   PubMed Web of Science ®Google Scholar
• Addeo R. A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). Expert Rev Anticancer Ther. 2017;17:199–201.
   PubMed Web of Science ®Google Scholar
• Prasad V, Kaestner V. Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 2017;44:132–135.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. Immunotherapy. 2016;8:1383–1391.
   PubMed Web of Science ®Google Scholar
• Deinlein T, Lax SF, Schwarz T, et al. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature. Eur J Cancer. 2017;83:99–102.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129:2437–2442.
   PubMed Web of Science ®Google Scholar
• Lai J, Xu P, Jiang X, et al. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report. BMC Cancer. 2017;17:507.
   PubMed Web of Science ®Google Scholar
• Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11:15.
   PubMed Web of Science ®Google Scholar
• Guggisberg K, Jordan RC. Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:98–104.
   PubMed Web of Science ®Google Scholar
• Argyris PP, Koutlas IG, Cooley S, et al. Angioimmunoblastic T-cell lymphoma of the oral cavity presenting as gingival mass: report of the histopathologic and molecular characteristics of an unusual case featuring clonal T-cell receptor gamma gene rearrangement by polymerase chain reaction. 2Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:e198–204.
   PubMed Web of Science ®Google Scholar
• Talreja KL, Barpande SR, Bhavthankar JD, et al. Precursor B-cell lymphoblastic lymphoma of oral cavity: A case report with its diagnostic workup. J Oral Maxillofac Pathol. 2016;20:133–136.
   PubMedGoogle Scholar
• Darling MR, Cuddy KK, Rizkalla K. Hodgkin lymphoma of the oral mucosa. Head Neck Pathol. 2012;6:507–510.
   PubMedGoogle Scholar
• Baden E, Al Saati T, Caveriviere P, et al. Hodgkin’s lymphoma of the oropharyngeal region: report of four cases and diagnostic value of monoclonal antibodies in detecting antigens associated with reed-sternberg cells. Oral Surg Oral Med Oral Pathol. 1987;64:88–94.
   PubMedGoogle Scholar
• Gonzalez-Fontal GR, Rosales JD, Jaramillo R, et al. Primary extranodal, extralymphatic hodgkin lymphoma of the mandible. Case Rep Med. 2011;387570:2011.
   Google Scholar
• Seoane J, Aguirre-Urizar JM, Esparza-Gomez G, et al. The spectrum of plasma cell neoplasia in oral pathology. Med Oral. 2003;8:269–280.
   PubMedGoogle Scholar
• Cardoso RC, Gerngross PJ, Hofstede TM, et al. The multiple oral presentations of multiple myeloma. Support Care Cancer. 2014;22:259–267.
   PubMed Web of Science ®Google Scholar
• Lee SH, Huang JJ, Pan WL, et al. Gingival mass as the primary manifestation of multiple myeloma: report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82:75–79.
   PubMed Web of Science ®Google Scholar
• Savarrio L, Gibson J, Dunlop DJ, et al. Spontaneous regression of an anaplastic large cell lymphoma in the oral cavity: first reported case and review of the literature. Oral Oncol. 1999;35:609–613.
   PubMed Web of Science ®Google Scholar
• Guevara-Canales JO, Sacsaquispe-Contreras SJ, Morales-Vadillo R, et al. Epidemiology of the sarcomas of the jaws in a Peruvian population. Med Oral Patol Oral Cir Bucal. 2012;17:e201–5.
   PubMed Web of Science ®Google Scholar
• Klepfish A, Schattner A, Shvidel L, et al. Successful treatment of aggressive HIV-associated non-Hodgkin’s lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option. Leuk Lymphoma. 2003;44:349–351.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin’s lymphoma. Ann Oncol. 2004;15:1805–1809.
   PubMed Web of Science ®Google Scholar
• Duman BB, Sahin B, Ergin M, et al. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature. Med Oncol. 2012;29:1223–1226.
   PubMed Web of Science ®Google Scholar
• Lopez JP, Jimeno A. Idelalisib for the treatment of indolent non-Hodgkin’s lymphoma. Drugs Today (Barc). 2014;50:113–120.
   PubMed Web of Science ®Google Scholar
• Jj B, Pujol E, Perez S, et al. Plasmablastic lymphoma of the oral cavity and jaws. AIDS. 2002;16:1979–1980.
   PubMed Web of Science ®Google Scholar
• Nikolaos N, Grigorios P, Konstantinos K, et al. Extranodal nasal-type NK/T-cell lymphoma of the palate and paranasal sinuses. Am J Case Rep. 2012;13:79–85.
   PubMedGoogle Scholar